Robert Coughlin, MassBio
December 14, 2020 09:41 AM ESTUpdated 02:17 PM
People
R&D

Mass­Bio head Cough­lin set to step down af­ter over­see­ing mas­sive bio­phar­ma ex­pan­sion in the state dur­ing 13-year tenure

Kyle Blankenship

The past decade has been good to bio­phar­ma, nowhere more so than the bustling and ever-ex­pand­ing life sci­ences hub in and around Boston. At the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times